Related Experiment Video
Updated: Apr 25, 2026
07:50
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
2.1K
[Thrombolytic agents].
Nihon Rinsho. Japanese Journal of Clinical Medicine
|August 29, 2014
Summary
Thrombolytic agents like tissue-type plasminogen activator (t-PA) dissolve blood clots by boosting plasmin activity. However, t-PA may cause brain tissue damage, prompting research into direct plasmin administration for stroke treatment.
Area of Science:
- Biochemistry
- Pharmacology
- Neurology
Context:
- Thrombolytic therapy is crucial for treating thrombotic events.
- Plasminogen activators (PAs) are the primary class of thrombolytic drugs.
- Tissue-type plasminogen activator (t-PA) offers targeted clot lysis with fewer systemic complications.
Purpose:
- To review the mechanism of thrombolytic agents, focusing on plasminogen activators.
- To discuss the potential neurotoxicity and blood-brain barrier damage associated with t-PA.
- To explore alternative thrombolytic strategies, such as direct plasmin administration.
Summary:
- Thrombolytic agents enhance plasmin activity to dissolve thrombi.
- Tissue-type plasminogen activator (t-PA) is preferred for its selectivity, but carries risks of neurotoxicity and blood-brain barrier damage.
- Delayed t-PA administration may worsen ischemic stroke outcomes.
- Intra-arterial plasmin administration is being investigated as a safer alternative due to plasmin's rapid inactivation in circulation.
Impact:
- Highlights the dual nature of t-PA, balancing therapeutic benefits with potential adverse effects.
- Underscores the need for optimized thrombolytic strategies in acute ischemic stroke.
- Suggests a promising avenue for future stroke treatment research focusing on localized plasmin delivery.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
746
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
746
01:16Clot Retraction and Fibrinolysis
5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K